Published in Bioorg Med Chem on October 05, 2005
Inside of the Linear Relation between Dependent and Independent Variables. Comput Math Methods Med (2015) 0.84
Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques. J Comput Aided Mol Des (2006) 0.82
Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks. Springerplus (2013) 0.81
Some QSAR studies for a group of sulfonamide Schiff base as carbonic anhydrase CA II inhibitors. Int J Mol Sci (2008) 0.80
A novel QSPR model for predicting θ (lower critical solution temperature) in polymer solutions using molecular descriptors. J Mol Model (2007) 0.79
Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis. ACS Med Chem Lett (2015) 0.77
A multidisciplinary decision support system for forest fire crisis management. Environ Manage (2004) 3.32
Anticancer and antiviral sulfonamides. Curr Med Chem (2003) 2.75
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett (2004) 2.33
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett (2005) 2.24
Synthesis and antimalarial activity of novel chiral and achiral benzenesulfonamides bearing 1, 3, 4-oxadiazole moieties. J Enzyme Inhib Med Chem (2007) 2.00
Collaborative development of predictive toxicology applications. J Cheminform (2010) 1.91
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget (2012) 1.77
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Oxovanadium(IV) complexes of hydrazides: potential antifungal agents. J Enzyme Inhib Med Chem (2006) 1.73
Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem (2004) 1.72
Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization. J Biol Chem (2008) 1.70
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem (2004) 1.57
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J Enzyme Inhib Med Chem (2004) 1.52
Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev (2012) 1.43
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A (2009) 1.43
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des (2005) 1.43
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett (2004) 1.42
Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem (2013) 1.42
Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem (2008) 1.42
Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem (2008) 1.40
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle (2013) 1.34
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett (2003) 1.32
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem (2007) 1.30
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides. Eur J Med Chem (2010) 1.30
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des (2008) 1.29
Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci (2006) 1.27
Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase. J Biol Inorg Chem (2009) 1.26
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorg Med Chem Lett (2005) 1.26
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett (2005) 1.25
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem (2006) 1.25
Metal-Based Antibacterial and Antifungal Agents: Synthesis, Characterization, and In Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), and Zn(II) Complexes With Amino Acid-Derived Compounds. Bioinorg Chem Appl (2006) 1.21
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur J Med Chem (2009) 1.20
Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem (2003) 1.19
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb) (2006) 1.19
A new coral carbonic anhydrase in Stylophora pistillata. Mar Biotechnol (NY) (2011) 1.18
Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa. J Physiol (2006) 1.17
Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry (2003) 1.17
Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem (2010) 1.16
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Root effect hemoglobin may have evolved to enhance general tissue oxygen delivery. Science (2013) 1.13
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem (2011) 1.13
Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc (2009) 1.13
Sulfamates and their therapeutic potential. Med Res Rev (2005) 1.12
In vitro antibacterial, antifungal & cytotoxic activity of some isonicotinoylhydrazide Schiff's bases and their cobalt (II), copper (II), nickel (II) and zinc (II) complexes. J Enzyme Inhib Med Chem (2006) 1.11
Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. J Enzyme Inhib Med Chem (2003) 1.10
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev (2012) 1.08
Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem (2010) 1.06
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res (2011) 1.05
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem (2011) 1.05
Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev (2006) 1.05
Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. J Enzyme Inhib Med Chem (2006) 1.05
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des (2008) 1.04
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem (2009) 1.04
A novel QSAR model for predicting induction of apoptosis by 4-aryl-4H-chromenes. Bioorg Med Chem (2006) 1.04
Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol (2012) 1.03
Synthesis of coumarin derivatives with cytotoxic, antibacterial and antifungal activity. J Enzyme Inhib Med Chem (2004) 1.03
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem (2002) 1.02
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol (2009) 1.02
CO2 permeability of cell membranes is regulated by membrane cholesterol and protein gas channels. FASEB J (2012) 1.02
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett (2005) 1.01
Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther (2010) 1.01
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta (2009) 1.00
Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol (2007) 1.00
Synthesis, characterization and biological studies of sulfonamide Schiff's bases and some of their metal derivatives. J Enzyme Inhib Med Chem (2011) 1.00
The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am J Physiol Cell Physiol (2002) 0.99
Membrane-bound carbonic anhydrases in osteoclasts. Bone (2006) 0.98
An update in the development of HIV entry inhibitors. Curr Top Med Chem (2007) 0.98
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety. Bioorg Med Chem Lett (2007) 0.97
Carbonic anhydrases in anthozoan corals-A review. Bioorg Med Chem (2012) 0.97
Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. J Med Chem (2010) 0.97
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem (2006) 0.97
Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev (2009) 0.96
In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J Enzyme Inhib Med Chem (2005) 0.96
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett (2004) 0.96
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett (2004) 0.96
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem (2009) 0.96
Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharmacol (2013) 0.96
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem (2014) 0.96
Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem (2002) 0.95
Adverse cardiovascular effects of the coxibs. J Med Chem (2005) 0.95
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem (2004) 0.95
Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl (2007) 0.95
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett (2003) 0.95
In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS One (2012) 0.94
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem (2008) 0.94
Carbonic anhydrase inhibitors: Schiff's bases of aromatic and heterocyclic sulfonamides and their metal complexes. J Enzyme Inhib Med Chem (2004) 0.94
Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds. ACS Chem Biol (2011) 0.93
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem (2012) 0.93
Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates. Bioorg Med Chem Lett (2008) 0.93
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett (2004) 0.93
In-vitro antibacterial and cytotoxic activity of cobalt (ii), copper (ii), nickel (ii) and zinc (ii) complexes of the antibiotic drug cephalothin (Keflin). J Enzyme Inhib Med Chem (2005) 0.93
Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol (2008) 0.93
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem (2005) 0.93
Extramitochondrial domain rich in carbonic anhydrase activity improves myocardial energetics. Proc Natl Acad Sci U S A (2013) 0.92
Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem (2011) 0.92